Company
AboutTeamImpact
Science
Development ModelFocus AreasPipeline
Partnering
Business ModelPartners
Proof
Case StudiesContact
Home / Development Model

How we develop.

From concept and formulation to regulatory batches and commercial supply, one integrated path.

Development Model

From known molecule to differentiated, scalable product.

We strategically invest in developing and commercializing a differentiated portfolio of niche, high-complexity pharmaceuticals — leveraging an experienced R&D team and a network of reliable CMO and CRO partners to drive a pipeline built to address real medical needs.

1Concept & Selection
2Formulation Development
3Scale-Up & Clinical Readiness
4Technology Transfer
5Regulatory Batches
6Commercial Supply
Licensable asset
Off Targets funds and carries the development riskSelection through to a de-risked, licensable asset
Delivered with the licensee or partnerTransfer, regulatory batches and supply
→Co-development and co-investment can begin from Stage 2
Licensing at the gate, before transfer
Stages 1 to 3Off Targets funds and carries the development risk
Licensable asset
Stages 4 to 6Transfer, regulatory batches and supply with the licensee or partner

Co-development and co-investment can begin from Stage 2.

STAGE 01

Concept & Selection

Molecules are evaluated against unmet need, market attractiveness, regulatory feasibility, competitive barriers, and licensing potential before development begins.

→
STAGE 02

Formulation Development

Complex injectable, sterile, and advanced-delivery formulations are engineered to create real clinical and commercial differentiation.

→
STAGE 03

Scale-Up & Clinical Readiness

Formulations are scaled and prepared for clinical development under defined, capital-efficient regulatory pathways. At the end of this stage the asset is in a licensable state.

→
STAGE 04

Technology Transfer

Following licensing or a co-development agreement, the asset package and process transfer to the partner or its chosen manufacturing site.

→
STAGE 05

Regulatory Batch Manufacturing

Registration and validation batches are manufactured under GMP conditions to support regulatory submission requirements.

→
STAGE 06

Commercial Manufacturing & Supply

Approved products transition to commercial-scale manufacturing and ongoing supply, through our CMO network or the licensee's site.

Regulatory Strategy

Known molecules change what has to be proven.

Off Targets programs are developed under 505(b)(2) and other defined regulatory pathways that allow a new formulation of a known molecule to rely, in part, on existing safety and efficacy data — rather than building a full clinical package from first principles.

NOVEL CHEMICAL ENTITY
  • Full nonclinical and clinical package built from first principles
  • Safety, efficacy, and dose all unproven at the outset
  • Regulatory and clinical risk concentrated in the earliest years
KNOWN MOLECULE, NEW FORMULATION
  • Existing safety and efficacy data for the active ingredient can be referenced
  • Development is focused on the formulation or delivery change itself
  • Regulatory risk concentrated in demonstrating performance, not first-in-human safety
Exclusivity & Protection

Exclusivity is earned, not assumed.

A 505(b)(2) pathway does not by itself confer market exclusivity. Protection is designed into each program deliberately, from several sources.

REGULATORY EXCLUSIVITY

Where the data supports it

Where a program generates new clinical investigations essential to approval, FDA may grant a period of three-year exclusivity for that change. Programs in orphan-designated indications may qualify for seven years.

PATENT PROTECTION

Our own filings

Formulation, process and delivery innovations are protected through our own patent filings, assessed alongside the patent landscape of each reference product.

TECHNICAL BARRIER

Complexity slows followers

Complex injectables and advanced-delivery formulations are harder to replicate than conventional dosage forms, which limits fast followers independent of any exclusivity period.

Eligibility is assessed case by case against FDA criteria and varies by program and jurisdiction.

Regulatory Execution

From submission to lifecycle management.

Regulatory strategy only creates value if it's executed and maintained — from first filing through the life of the approval.

IN Submissions

  • Compilation and filing of 505(b)(2) and equivalent regional dossiers
  • Regulatory strategy coordinated across US, UK, EU, and India frameworks
  • Response management for regulatory queries and information requests

OUT Approval Management

  • Post-approval variations and label updates
  • Renewal and lifecycle management of existing approvals
  • Ongoing regulatory compliance through commercial supply
Next step

Discuss a program, licence or collaboration.